Supreme Court's Genentech Patent Ruling May Hinder IP Deals; Academia, Biotech at Risk

The ruling allows MedImmune to challenge a fundamental Genentech patent while Genentech continues to out-license the IP. The result could compel licensees to more readily challenge patents even after obtaining a license and embolden licensors to seek higher upfront payments to offset the risk of losing out on future royalties.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.